Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3451
John B. Sanfilippo & Son
JBSS
$801M
| $917K | ﹤0.01% |
12,988
+1,876
| +17% | +$127K |
2016 Q3
37 quarters
|
|
3452
Richtech Robotics
RR
$378M
| $916K | ﹤0.01% |
283,688
+184,774
| +187% | +$817K |
2025 Q2
2 quarters
|
|
3453
Shenandoah Telecom
SHEN
$601M
| $916K | ﹤0.01% |
79,220
+7,290
| +10% | +$86.2K |
2013 Q2
50 quarters
|
|
|
RZLV
3454
Rezolve AI
RZLV
$859M
| $912K | ﹤0.01% |
354,837
+108,038
| +44% | +$408K |
2025 Q2
2 quarters
|
|
3455
Eagle Bancorp Montana
EBMT
$169M
| $911K | ﹤0.01% |
45,772
+1,980
| +5% | +$34.4K |
2020 Q2
22 quarters
|
|
|
SKYT
3456
DELISTED
SkyWater Technology
SKYT
| $908K | ﹤0.01% |
50,002
+12,402
| +33% | +$215K |
2022 Q1
15 quarters
|
|
3457
BlackSky Technology
BKSY
$897M
| $907K | ﹤0.01% |
48,399
+3,741
| +8% | +$76.3K |
2023 Q1
11 quarters
|
|
3458
Redwire
RDW
$2.72B
| $906K | ﹤0.01% |
119,202
-251,635
| -68% | -$1.85M |
2022 Q2
14 quarters
|
|
|
UDMY
3459
DELISTED
Udemy
UDMY
| $905K | ﹤0.01% |
154,766
-17,143
| -10% | -$100K |
2022 Q1
15 quarters
|
|
3460
Vitesse Energy
VTS
$710M
| $905K | ﹤0.01% |
46,983
+3,475
| +8% | +$74.2K |
2023 Q1
11 quarters
|
|
3461
CALL
UiPath
PATH
$6.84B
| $905K | ﹤0.01% |
+55,200
| New | +$859K |
2025 Q4
0 quarters
|
|
3462
Republic Bancorp
RBCAA
$1.84B
| $900K | ﹤0.01% |
13,044
+1,246
| +11% | +$86.3K |
2016 Q1
39 quarters
|
|
|
EFXT
3463
Enerflex
EFXT
$3B
| $898K | ﹤0.01% |
58,211
+42,771
| +277% | +$569K |
2023 Q1
11 quarters
|
|
3464
Zevra Therapeutics
ZVRA
$593M
| $897K | ﹤0.01% |
100,135
-232,308
| -70% | -$2.2M |
2022 Q3
13 quarters
|
|
3465
Hackett Group
HCKT
$268M
| $897K | ﹤0.01% |
45,706
+3,436
| +8% | +$65.2K |
2013 Q2
50 quarters
|
|
3466
Aehr Test Systems
AEHR
$3.5B
| $896K | ﹤0.01% |
44,380
+4,160
| +10% | +$101K |
2022 Q3
13 quarters
|
|
|
RPC
3467
Ridgepost Capital
RPC
$840M
| $895K | ﹤0.01% |
91,233
-86,040
| -49% | -$872K |
2023 Q2
10 quarters
|
|
3468
The RMR Group
RMR
$303M
| $894K | ﹤0.01% |
59,989
+2,296
| +4% | +$35K |
2019 Q1
27 quarters
|
|
3469
Orion Group Holdings
ORN
$377M
| $894K | ﹤0.01% |
89,908
+888
| +1% | +$8.61K |
2023 Q3
9 quarters
|
|
3470
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$553M
| $893K | ﹤0.01% |
+5,600
| New | +$769K |
2025 Q4
0 quarters
|
|
3471
MGP Ingredients
MGPI
$274M
| $891K | ﹤0.01% |
36,658
+5,674
| +18% | +$138K |
2016 Q1
39 quarters
|
|
|
AHL
3472
DELISTED
Aspen Insurance
AHL
| $890K | ﹤0.01% |
23,999
+2,283
| +11% | +$84.2K |
2025 Q2
2 quarters
|
|
|
VOYG
3473
Voyager Technologies
VOYG
$1.89B
| $890K | ﹤0.01% |
34,050
+14,706
| +76% | +$399K |
2025 Q3
1 quarter
|
|
3474
Seneca Foods Class A
SENEA
$1.2B
| $889K | ﹤0.01% |
8,038
+1,477
| +23% | +$169K |
2016 Q1
39 quarters
|
|
3475
PUT
Corcept Therapeutics
CORT
$12.6B
| $887K | ﹤0.01% |
25,500
-71,400
| -74% | -$5.61M |
2024 Q3
5 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.